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The anti-VEGF receptor 2 antibody IMC-1121B is
a promising antiangiogenic drug being tested for
treatment of breast and gastric cancer. We have
determined the structure of the 1121B Fab fragment
in complex with domain 3 of VEGFR2, as well as the
structure of a different neutralizing anti-VEGFR2 anti-
body, 6.64, also in complex with VEGFR2 domain 3.
The two Fab fragments bind at opposite ends of
VEGFR2 domain 3; 1121B directly blocks VEGF
binding, whereas 6.64 may prevent receptor dimer-
ization by perturbing the domain 3:domain 4 inter-
face. Mutagenesis reveals that residues essential
for VEGF, 1121B, and 6.64 binding are nonover-
lapping among the three contact patches.
INTRODUCTION
The process of blood vessel growth and maturation is funda-
mentally important to the growth and survival of all animals
with a circulatory system (Roskoski, 2007b). New blood vessels
can develop from two closely related processes: vasculo-
genesis, the assembly of vessels from precursor cells, and
angiogenesis, the sprouting of new vessels from a preexisting
network (Roskoski, 2007b). Both processes are critical during
embryonic development, and angiogenesis remains essential
in the mature organism, especially for functions such as wound
repair and growth of the endometrial lining (Ferrara, 2004;
Folkman, 1995). However, angiogenesis also underlies a number
of pathological processes, including diabetic retinopathy, age-
related macular degeneration, and psoriasis (Chua and Arbiser,
2009; Ferrara, 2004). In particular, angiogenesis is necessary
for the pathogenesis of solid tumors, which are unable to grow
beyond a small size without the formation of an extensive
vascular network (Folkman, 1995).
The key players in the process of angiogenesis are the
vascular endothelial growth factors (VEGFs) and their receptors.
In humans, there are four closely related VEGFmolecules, desig-
nated VEGF-A, -B, -C, and -D (Roskoski, 2007b), and threeStructure 19, 1097–known VEGF receptors: VEGFR1, also known as Flt-1 (fms-like
tyrosine kinase 1) (de Vries et al., 1992; Shibuya et al., 1990);
VEGFR2, also known as KDR (kinase insert domain receptor)
(Terman et al., 1991, 1992); and VEGFR3, or Flt-4 (Pajusola
et al., 1992). The VEGF receptors are class V of the receptor tyro-
sine kinases (Grassot et al., 2006), and contain seven Ig-like
domains in their extracellular portion, a single transmembrane
helix, and an intracellular kinase domain (Ferrara, 2004;
Roskoski, 2008). Of all the possible interactions between these
ligands and receptors, the most important for angiogenesis is
the one between VEGF-A and KDR (Ferrara, 2004; Shalaby
et al., 1995). Flt-1 may represent a regulatory ‘‘decoy’’ receptor
for VEGF-A and -B (Hiratsuka et al., 1998; Meyer et al., 2006;
Park et al., 1994), whereas VEGF-C and -D interactions with
Flt-4 are primarily important in lymphangiogenesis (Kaipainen
et al., 1995; Tammela and Alitalo, 2010). Mature VEGF-A (here-
after referred to simply as VEGF) is a disulfide-linked homodimer
in which the receptor binding domain contains two identical
binding sites, at opposite ends of the domain, formed by resi-
dues from both chains (Wiesmann et al., 1997). Bound VEGF is
therefore thought to bridge two receptor molecules, forming
a dimer; this hypothesis is supported by electron microscopy
of VEGF:KDR complexes (Ruch et al., 2007). A KDR homodimer
is thought to be the main conduit for VEGF signaling (Ferrara,
2004; Holmes et al., 2007); however, heterodimers involving
other VEGF receptors may also transduce a signal (Huang
et al., 2001; Neagoe et al., 2005).
The structural details of the VEGF-VEGF receptor interaction
have been gradually elucidated over the last dozen years.
Domain deletion experiments have localized the VEGF binding
site to domains 2 and 3, with domain 2 seeming to play a domi-
nant role (Fuh et al., 1998; Lu et al., 2000). For Flt-1, domain 2
alone is necessary and sufficient for high-affinity binding,
although domain 3 enhances affinity (Wiesmann et al., 1997). In
contrast, KDR constructs lacking domain 3 bind VEGF weakly
or not at all, but domain 2 is also required (Fuh et al., 1998; Lu
et al., 2000). A crystal structure of a truncated form of VEGF (resi-
dues 8–109) bound to domain 2 of Flt-1 shows that the C
terminus of domain 2 lies in a groove at one end of the VEGF
dimer, suggesting that the beginning of domain 3 must be in
close proximity (Wiesmann et al., 1997). A recent structure of
KDR domains 2 and 3 bound to VEGF-C confirms this prediction,1107, August 10, 2011 ª2011 Elsevier Ltd All rights reserved 1097
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Structure of Antibodies Bound to VEGF Receptor 2showing the ligand bound at the interface between domains 2
and 3 (Leppa¨nen et al., 2010). The detailed interactions between
VEGF-C and KDR can, in many cases, serve as a model for the
VEGF-A:KDR complex.
Given the importance of angiogenesis for cancer progression
(Folkman, 1995), it is not surprising that an intense effort has
been made to interfere with this process, and in particular with
VEGF:KDR-mediated signaling, for the treatment of cancer (Ellis
and Hicklin, 2008; Hsu andWakelee, 2009). It is possible to block
signal transduction via the VEGF receptors by inhibiting receptor
tyrosine kinase activity; although ligand still binds the receptor,
no signal is then sent to the rest of the cell (Ivy et al., 2009).
Two such kinase inhibitors are on the market, namely sunitinib
(Sutent; Pfizer) (Mendel et al., 2003), which is fairly specific to
the VEGF and platelet-derived growth factor (PDGF) receptors
(Roskoski, 2007a), and sorafenib (Nexavar; Bayer) (Wilhelm
et al., 2004), which inhibits the VEGF receptors, PDGF receptors,
and Raf (Wilhelm et al., 2008). It is also possible to prevent VEGF
binding to KDR, by binding an interfering molecule to either the
ligand or the receptor. Examples of the first approach include
an anti-VEGF antibody such as bevacizumab (Avastin; Genen-
tech) (Hurwitz et al., 2004) and a receptor mimic such as
VEGF-Trap (Regeneron) (Holash et al., 2002). The second
approach is exemplified by IMC-1121B (ramucirumab; ImClone
Systems) and 6.64 (ImClone Systems), two antibodies directed
against KDR (Lu et al., 2003; Witte et al., 1998).
IMC-1121B (hereafter shortened to ‘‘1121B’’) is very effective
at blocking VEGF binding to KDR, as well as receptor phosphor-
ylation and farther downstream signaling events (Miao et al.,
2006). 1121B has demonstrated some antitumor efficacy in
humans, including a decrease in tumor vascularity (Spratlin
et al., 2010); additionally, a surrogate antibody directed against
murine KDR inhibits angiogenesis (Prewett et al., 1999). Early
on in the research effort that led to the (fully human) 1121B anti-
body, a murine anti-KDR antibody called ‘‘6.64’’ was identified
as having VEGF-blocking ability (Lu et al., 2000). 6.64 was also
shown to interfere with VEGF-mediated signaling pathways in
the cell (Lu et al., 2003; Witte et al., 1998), but was not ultimately
on the pathway that led to the tighter-binding and more effective
1121B. Both of these antibodies were shown to bind to KDR
domain 3 exclusively, although they did not interfere with one
another’s binding (Lu et al., 2003).
We began this study hoping that a crystal structure of 1121B
bound to KDRwould explain the molecular mechanism by which
1121B interferes with VEGF signaling. In the course of deter-
mining this structure, we also solved the structure of 6.64 bound
to KDR, and discovered that the two antibodies must block
VEGF binding in two different ways, because it was hard to
imagine how they could both occlude the same ligand binding
site on KDR. We then carried out mutagenesis and binding
experiments that have shown how both of these antibodies
work to block VEGF signaling through KDR.
RESULTS
Structure Determination
In the course of determining the KDR d3:1121B Fab complex
structure presented here, we also determined two other struc-
tures: the 1121B Fab fragment alone and the complex of KDR1098 Structure 19, 1097–1107, August 10, 2011 ª2011 Elsevier Ltd Ad3 with the Fab fragment of 6.64 (Table 1 and Figure 1; see Fig-
ure S1 available online). The 1121B structure was solved first to
2.2 A˚, using the cetuximab Fab fragment from the cetuximab:
EGFR structure (Li et al., 2005) as a molecular replacement
search model. Separately, we determined the KDR d3:6.64
complex structure to 2.2 A˚ (Figure 1A) by molecular replacement
with a structurally similar (but functionally unrelated) anticollagen
Fab (Uysal et al., 2008); this partial solution provided clear
enough electron density (Figure 1C) to allow us to build a model
covering the entirety of KDR domain 3 (Figure 1D). Finally, we
used the 1121B Fab and KDR domain 3 as molecular replace-
ment search models to determine the KDR d3:1121B structure
(Figure 1C) (a more detailed description of the structure determi-
nation can be found in Supplemental Experimental Procedures).
The KDR d3:1121B complex crystallized in two space groups
(P43212 and P3221) from the same growth condition, sometimes
even from the same drop. We solved both structures, and found
that the higher-resolution P43212 structure has good electron
density for the entire Fab and for the portion of KDR proximal to
the Fab interface (Figure 1E); however, the density becomes
less clear for the distal parts of KDR, probably due to a lack of
stabilizing crystal contacts. The P3221 complex (Figure 1B),
despite its somewhat lower resolution, has good electron density
for all of KDR domain 3, with a well-defined main chain and most
side chains visible throughout the entire domain. Because the
two structures are very similar (Ca root-mean-square deviation
[rmsd] 1.2 A˚ over the entire complex, 0.8 A˚ considering only the
KDR and Fv regions), we have used the P3221 structure to look
at the large-scale features of the complex, and the P43212 struc-
ture to analyze the detailed antibody-receptor interactions.
The KDR d3:6.64 Complex
The structure of KDR domain 3, as seen in the KDR d3:6.64
complex, can be defined structurally as starting at Gly220 and
ending at Pro328 (Figure 1D). The overall fold fits well in the class
of Ig-like domains, with two antiparallel three- to four-stranded
b sheets stacked in a sandwich. Our domain 3 structure is gener-
ally in excellent agreement with the recent structure of the KDR
d2–d3:VEGF-C complex (Leppa¨nen et al., 2010), with an overall
Ca rmsd of 1.1 A˚ on domain 3 and only a few localized differ-
ences (see Discussion). The 6.64 Fab binds to a fairly extended
area of KDR domain 3, mostly near the end of the domain con-
taining the C terminus (Figures 2A and 2B). The Fab makes
a few interactions with the very C-terminal end of our model;
however, it should be noted that our domain 3 construct (KDR
residues 220–338) is too long; it extends well past the domain
3-domain 4 boundary at residue 328, so residues 328–330 in
our model are not in a biologically relevant conformation. All
six of the 6.64 antibody complementarity-determining regions
(CDRs) make interactions with KDR domain 3, including one
close contact between Gly33 of the Fab light chain (amino acids
in the 6.64 and KDR Fabs are numbered sequentially instead of
by Kabat, Chothia, or other conventions) and one of the sugars in
the N-glycosylation of KDR residue 245 (Figure 2A). The 6.64
binding epitope on KDR is highly discontinuous, with contacting
residues scattered over five stretches of primary sequence (Fig-
ure 2B; see Figure S2A for a detailed list of contacts). A total of
982 A˚2 of solvent-accessible surface area on KDR domain 3 is
buried in the 6.64 interface (residues 328–330 are excluded, asll rights reserved
Table 1. Data Collection and Refinement Statistics
KDR:1121B Complex, Form 1 KDR:1121B Complex, Form 2 KDR:6.64 Complex 1121B Fab
Data Collection Statistics
Space group P43212 P3221 C2221 P3221
Unit cell (A˚) 63.9, 63.9, 275.0 64.9, 64.9, 263.2 78.9, 112.1, 157.0 66.6, 66.6, 203.7
Site of data collection NSLS X4A APS 31-ID (LRL-CAT) APS 31-ID (LRL-CAT) Home source
Unique reflections 16,605 11,083 34,976 26,790
Resolution (A˚) 50–2.7 2.80–2.70 55–3.2 3.37–3.2 40–2.2 2.32–2.20 100–2.2 2.28–2.20
Rsym 0.106 0.553 0.099 0.688 0.124 0.619 0.060 0.219
Completeness (%) 99.8 99.1 98.6 98.8 98.2 97.7 97.5 78.7
Average redundancy 12.5 10.7 10.2 10.5 7.2 7.3 7.0 3.3
I/s(I) 32.7 3.2 20.8 3.2 13.7 3.2 20.5 4.5
Refinement Statistics
Resolution (A˚) 50–2.7 55–3.2 40–2.2 70–2.2
Reflections used (free) 15,653 (831) 10,548 (522) 33,185 (1,790) 25,334 (1,345)
R factor 0.282 0.277 0.203 0.183
Rfree 0.315 0.332 0.259 0.223
Rmsd
Bonds (A˚) 0.004 0.004 0.013 0.012
Angles () 0.75 0.76 1.50 1.40
Ramachandran statistics
Most favored (%) 94.3 93.0 96.6 96.4
Additional allowed (%) 5.5 6.8 3.0 3.4
Outliers (%) 0.2 0.2 0.4 0.2
Model contents
Fab residues 430 429 434 429
KDR residues 110 112 112 0
Waters 0 0 375 257
Other ligands 4 NAG, 6 Ca2+ 1 PO4
PDB ID code 3S37 3S36 3S35 3S34
All four crystal forms have onemolecule per asymmetric unit. APS, Advanced Photon Source; NSLS, National Synchrotron Light Source; NAG, N-ace-
tylglucosamine; PO4, phosphate ion.
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Structure of Antibodies Bound to VEGF Receptor 2they will be for all subsequent calculations), of which 55% is in
the heavy-chain interface and 45% is in the light-chain interface.
Including the Fab side of the interface, the total buried surface
area is 2032 A˚2; for comparison, the buried surface area in the
cetuximab:EGFR complex is 1770 A˚2 (Li et al., 2005), and in
the bevacizumab:VEGF complex is about 1750 A˚2 (Muller
et al., 1998).
The KDR d3:1121B Complex
The 1121B Fab binds to KDR domain 3 at the end of the domain
closest to the N terminus (Figure 1B). This is almost diametrically
opposite the binding site of 6.64 (Figure 1A), which validates the
previous observation that 1121B and 6.64 do not compete with
one another and can simultaneously bind to KDR (Lu et al.,
2003). Gly220, the linker residue between KDR domains 2 and
3, is directly contacted by the Fab (Figures 2D and 2E), as are
a number of residues in its vicinity. The 1121B binding epitope
is much more localized than that of 6.64, consisting almost
exclusively of a short b hairpin (KDR residues 312–317), an adja-
cent stretch of b strand (residues 251, 255, 257, 259, and 261),
and the N terminus of domain 3 (residues 220–222) (FiguresStructure 19, 1097–2C–2E). The light chain of the 1121B Fab plays a fairly small
role in this interaction, making a few hydrophobic contacts and
one charge pair (between Lys92 of the light chain and Glu251
of KDR) (Figure 2E; detailed interactions can be found in Fig-
ure S2B). This asymmetry can also be seen in the buried
solvent-accessible surface area: of the total 1001 A˚2 buried on
KDR domain 3, 67% is in the heavy-chain interface and only
33% is in the light-chain interface. (The total buried area
including the Fab is 1922 A˚2, somewhat less than for the 6.64
complex.) It should be noted, however, that the N terminus of
KDR domain 3 points in the direction of the light-chain CDRs,
and modeling based on the KDR:VEGF-C structure (Leppa¨nen
et al., 2010) indicates probable contacts between the light chain
and KDR domain 2 (see Discussion).
The 1121B Fab fragment has changed conformation very
little from the unbound structure to the KDR domain 3-bound
structure. The elbow angle between variable and constant
domains of the Fab has changed by less than 5, and the Ca
rmsd in the Fv region is only 0.46 A˚, with some minor (<0.5 A˚)
rigid-body movements of the various CDRs. The only side-
chain adjustment of note is a flip of Phe94 of the light chain1107, August 10, 2011 ª2011 Elsevier Ltd All rights reserved 1099
Figure 1. Structures of KDR Domain 3
Bound to 1121B and 6.64 Fabs
(A) Overview of the KDR:6.64 complex. A
cartoon representation of the 6.64 Fab bound
to domain 3 of KDR is shown with the Fab
heavy chain in dark blue, the Fab light chain in
light blue, and KDR domain 3 in magenta. The
domain 3 N terminus is indicated at the upper
right, and the C terminus is near the center of the
image.
(B) Overview of the KDR:1121B complex. A
cartoon representation of the 1121B Fab bound
to KDR domain 3 is shown aligned so that the
KDR portion superimposes on the KDR portion of
the complex in (A). As above, KDR domain 3 is
in magenta, while the 1121B Fab heavy chain is in
dark yellow and the light chain is in light yellow.
This color coding will be maintained in all subse-
quent figures.
(C) Electron density from the KDR:6.64 complex.
A 2mFo  DFc map is shown as a blue mesh,
contoured at 1 s, in a region at the interface of
KDR, the Fab heavy chain, and the Fab light chain.
Selected residues from the three chains are
labeled; LC indicates the Fab light chain, and HC
indicates the Fab heavy chain.
(D) A cartoon view of KDR domain 3. Secondary-structure elements have been labeled, and the N and C termini are labeled for comparison with other figures.
(E) Electron density from the KDR:1121B complex, depicted as in (C). The Fab light chain is colored yellow, and is visible on the left side of the image.
See also Figure S1.
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150 in the bound structure) to open up a pocket for Leu313 in the
ligand (Figure 2E). Tyr57 and Tyr59 of the heavy chain, which are
in that same area, have reoriented slightly to accommodate the
bound KDR.
The structure of KDR domain 3 also seems not to be changed
dramatically upon 1121B binding. In addition to the differences
noted above versus the Leppa¨nen et al. structure, the 6.64-
bound and 1121B-bound structures can be compared against
one another. In doing this analysis, we must keep in mind that
the 1121B-bound structure is derived from the 6.64-bound
structure; however, we think that our refinement is sufficiently
robust that any model bias arising from the parental structure
has been removed. The overall Ca rmsd between the 6.64-
and 1121B-bound KDR structures is 0.51 A˚. Themost noticeable
change in the 1121B-contacting portion of KDR domain 3 is a
1.5 A˚ movement of Met314 away from 1121B in order to relieve
a steric clash with the main-chain oxygen of Thr100 on the heavy
chain (Figure 1E). Met314 is pushed toward the rest of KDR
domain 3, forcing a number of small shifts in the surrounding
residues to accommodate it.
Mutagenesis and Binding Assays
To probe the functional importance of the residues involved in
the 1121B and 6.64 binding interfaces, and to assess their
contribution to VEGF binding, a series of alanine mutants was
designed. Five of these mutants (M1–M5) were designed to
cover small clusters of the primary sequence for ease of muta-
genesis while blanketing the entire top (domain 2-proximal)
surface of KDR domain 3 (Table 2 and Figures 3A and 3B). An
additional two mutants (M6–M7) were designed along similar
principles but were targeted to the 6.64 binding interface (Table1100 Structure 19, 1097–1107, August 10, 2011 ª2011 Elsevier Ltd A2 and Figures 3A and 3C). The final set of mutants targeted the
KDR d2–d3 linker (M8), a patch on b strand 3 (M9), and the region
of M1 (M1a–M1g) (Table 2; Table S1). All of the residues selected
for alanine mutation are surface exposed and should not affect
packing in the hydrophobic core of KDR domain 3. The first
seven mutants (M1–M7) were expressed in constructs contain-
ing KDR domains 1–3 (residues 20–328, following the signal
sequence) or domains 2–3 (residues 122–328), followed by an
Fc fusion. The final set of mutants (M1a–M1g, M8, and M9)
were expressed using the d2–3 construct only. It should be
noted that these proteins are expressed and used in the assays
as dimers, containing two copies of the KDR construct joined by
disulfide links in their Fc tags. This dimeric receptor construct
may bind VEGF more tightly than would an otherwise identical
monomeric construct.
The mutant receptors were purified and assayed for binding
to 1121B, 6.64, and VEGF-165. Binding data for d1–3 constructs
M2–M7 and d2–3 M8 are shown in Figure 4 and Table 2;
additional binding data for other d2–3 constructs is shown in
Figure S3 and Table S1. Mutants M1 and M9 did not express
at all in either the d1–3 or the d2–3 construct (Table S2); this
may indicate a protein-folding defect in these mutants, even
though the core of the domain is untouched. A series of
follow-up mutants in the region of M1 identified one (M1a) that
did not detectably bind either VEGF or 1121B (Figure S3 and
Table S1); however, this mutant’s low expression level (Table
S2) and weak binding to 6.64 suggest that it, too, may have
a folding problem in this region. The other constructs expressed
robustly (Table S2). Mutant M5 severely affected 1121B bind-
ing, without altering the affinity for either 6.64 or VEGF. Con-
versely, mutant M7 abolished 6.64 binding completely, but had
no effect on either 1121B or VEGF binding.MutantM6 eliminatedll rights reserved
Figure 2. Details of the KDR-Antibody Interfaces
(A) Details of the KDR:6.64 interface. Themolecular surface of KDR domain 3 is shown. Atomswhich directly contact (<3.5 A˚ distance) an atom of the 6.64 Fab are
colored red, while atoms which are close to the Fab (<5 A˚ distance) are colored pink. The six CDRs of the 6.64 Fab are shown as ribbons, colored as in Figure 1A.
The large protrusion from the top center of the KDR surface in this view is one of the two N-glycosylations in the structure. The positions of the N and C termini of
the KDR model are indicated.
(B) A cartoon view of KDR domain 3, in exactly the same orientation as (A). If any atom of a particular residue was colored red in (A), the backbone is colored red
here. If an atom was colored pink (but none were red), the backbone is pink here. Selected secondary-structure elements are labeled.
(C) Details of the KDR:1121B interface. KDR domain 3 is depicted as in (A), but here shows interactions with the 1121B Fab. The CDRs of the Fab are shown,
colored as in Figure 1C, except for CDR L2, which makes no contacts.
(D) A cartoon view equivalent to (B), but for the KDR:1121B interface. The orientation of (C) and (D) is related to that of (A) and (B) by an approximate 90 rotation
about a horizontal axis.
(E) Details of the KDR d3:1121B interface. The backbones of KDR and 1121B are shown in cartoon representation, with KDR d3 colored pink, the 1121B light
chain in yellow, and the 1121B heavy chain in brown. Side chains which form interactions between KDR and 1121B are shown in stick form. KDR residues are
identified by residue number only, while 1121B heavy-chain residues have the prefix ‘‘H’’ and light-chain residues have the prefix ‘‘L.’’
See Figure S2 for another depiction of the KDR-1121B contacts.
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Structure of Antibodies Bound to VEGF Receptor 2binding to 6.64, but also reduced affinity for 1121B and VEGF;
this mutant may also have destabilized the structure of the
KDR domain. Finally, mutant M2 shows a lower affinity for
VEGF without appreciably affecting the binding to 1121B or to
6.64.
To further understand the relationships between the two
antibody binding sites and the VEGF binding site, we tested
1121B and 6.64 for their ability to block KDR binding to VEGF.
We examined three KDR constructs: the d1–3-Fc construct
described above, a d1–7-AP fusion used in our previous work
(Lu et al., 2000), and a commercially available d1–7-Fc fusion.
Like the Fc fusions, the AP fusion protein is dimeric in solution,
and the three proteins have similar affinities for the two anti-
bodies and for VEGF (Table 2). However, the blocking behavior
is very different. 1121B blocks VEGF binding to all three
constructs with roughly similar affinity (Figure 5A); the higher
EC50 for blocking the d1–7-Fc fusion can be explained by the
higher affinity this fusion has for VEGF (Table 2). The blocking
ability of 6.64, however, is almost completely eliminated with
the Fc fusions (Figure 5B), despite the fact that 6.64 binds to
these constructs with nearly the same affinity as it does to
d1–7-AP (Table 2).Structure 19, 1097–DISCUSSION
The most striking feature of the KDR:1121B structure compared
to the KDR:6.64 structure is how the two Fabs bind almost at
opposite poles of KDR domain 3, with 1121B at the domain
2-proximal end and 6.64 at the domain 4-proximal end (Fig-
ure 6A). The binding surfaces of the two Fabs do not overlap at
all (Figure 2), suggesting that both antibodies could even bind
simultaneously to the same molecule of KDR. This is consistent
with previous data showing that KDR, even when fully saturated
with one of these two antibodies, still has room to bind the other
(Lu et al., 2003). The disjunction of the two antibody binding
epitopes raises the question: how can both of these antibodies
interfere with VEGF binding to KDR?
Thanks to the recently published structure of VEGF-C bound
to KDR domains 2 and 3 (Leppa¨nen et al., 2010), we have
a much clearer picture of how 1121B and 6.64 work as VEGF
blockers. This structure is not a perfect model for the
VEGF-A:KDR complex, because there are small but significant
differences in the relative orientation of the ligand and domain 2
of the receptor when compared to the Flt-1 domain 2:VEGF-A
crystal structure (Wiesmann et al., 1997). However, it serves for1107, August 10, 2011 ª2011 Elsevier Ltd All rights reserved 1101
Table 2. KDR Mutant Binding Constants
Binding KD (nM)
KDR Construct Mutation 1121B Fab 6.64 Fab VEGF
d1–7-AP Wild-type 0.070 0.30 2.42
d1–7-Fc Wild-type 0.113 0.97 0.20
d1–3-Fc Wild-type 0.056 0.36 2.28
d2–3-Fc Wild-type 0.057 0.58 3.25
d1–3 M1 220GYRIYD/AAAIAA nd nd nd
d1–3 M2 251ELN/AAA 0.133 0.80 23.3
d1–3 M3 278KTQS/AAAA 0.086 1.30 1.89
d1–3 M4 282GSEMKK/AAEAKA 0.090 1.05 1.71
d1–3 M5 312GLMTK/AAATA 28.0 1.15 1.69
d1–3 M6 238VGEKLV/AAAALA 0.223 2.52 2.80
d1–3 M7 295DGVTR/AAVAA 0.089 nb 1.07
d2–3 M8 217VVVG/AAAA 0.084 0.52 7.12
d2–3 M9 255GIDFN/AIAFA nd nd nd
nb, no detectable binding; nd, binding not determined because construct
did not express.
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Structure of Antibodies Bound to VEGF Receptor 2the purpose at hand. A superposition of the KDR:1121B struc-
ture onto the KDR:VEGF-C structure reveals that there is an
overlap in the position of a loop in VEGF-C (residues 189–194)
and CDR H2 (residues 57–59) of 1121B (Figure 6B). This loop
is two residues shorter in VEGF-A, which is not enough to relieve
the steric clash, and it is highly unlikely that either the VEGF or the
1121B structure could be distorted to avoid the overlap without
a substantial energetic penalty. We also observe some steric
interference between KDR domain 2 and the light chain of
1121B (Figure 6A). Although this clash could be relieved by1102 Structure 19, 1097–1107, August 10, 2011 ª2011 Elsevier Ltd Aa fairly small motion of domain 2, that same motion would alter
the VEGF binding site, perhaps to a degree incompatible with
VEGF binding. Therefore, 1121B blocks VEGF signaling in two
ways: by sterically preventing the ligand from binding to KDR,
and by changing the receptor conformation so that it cannot
bind ligand.
The mechanism of 6.64 action is less obvious. When the
KDR:6.64 structure is superimposed onto the KDR:VEGF-C
structure, there is no overlap between the antibody and the
VEGF; the closest pair of Ca atoms is about 15 A˚ apart. There-
fore, 6.64 is not a direct blocker like 1121B. 6.64 does not appear
to sterically prevent receptor dimerization in the manner of per-
tuzumab (Franklin et al., 2004), because a dimeric Fab:receptor:
ligand model can be constructed with no overlaps (Figure 6C). It
is possible that 6.64 binding could cause a conformational
change in KDR domain 3 that prevents VEGF binding. However,
comparison of our 6.64-bound and 1121B-bound structures (see
above) showed no differences likely to affect VEGF binding.
We did observe a difference when comparing our structures to
the KDR d2–d3:VEGF-C structure (Leppa¨nen et al., 2010) in
the area of residues 268–282. In the Leppa¨nen et al. structure,
this region is a fairly simple b strand formed by residues 269–
276, with a large loop connecting it to the b strand we are calling
b5 (Figure 1D). In our structure, by contrast, residues 268–272
form one turn of an a helix, followed by a bulged b strand in which
residues 278–282 are offset by two positions from their locations
in the Leppa¨nen et al. structure (Figure S1B). Two of the residues
in this area, Lys271 and Arg275, make contacts with the 6.64
Fab, so it is possible that Fab binding has induced this change.
We think this is unlikely because our 1121B-bound structure
looks the same as the 6.64-bound structure in this region, and
because Leppa¨nen et al. note that this portion of their structureFigure 3. A Schematic of the KDR Muta-
genesis
(A) The sequence of KDR domain 3 is shown, with
the residues involved in mutants M1–M7 and M9
colored red. Residues contacting the 1121B light
chain have a yellow dot above them, while resi-
dues contacting the 1121B heavy chain have
a brown dot above them; if a residue contacts both
chains of the Fab, it has both dots above it. Simi-
larly, light blue and dark blue dots are used to
indicate contacts to the 6.64 light and heavy
chains, respectively. See Figure S2 for a detailed
list of antibody-KDR contacts.
(B) The top (domain 2-proximal) surface of KDR
domain 3 is shown, with the N terminus indicated.
Residues colored red were mutated to alanine; the
surface patches corresponding to particular
mutants are delineated by black lines. The two
uncolored patches in the middle of the surface
correspond to main-chain atoms of unmutated
(hydrophobic core) residues. The bound 1121B
Fab is shown in cartoon representation.
(C) The surface of KDR domain 3 is shown in the
same orientation as Figure 2A, with the 6.64 CDRs
drawn as thin Ca traces for reference. The red
surface corresponds to mutants M6 and M7,
separated by the black line as indicated.
See also Table S2 for KDR mutant expression
levels.
ll rights reserved
Figure 5. KDR-Blocking ELISAs
(A) 1121B Fab blocking the binding of KDR d1–3-Fc, d1–7-Fc, or d1–7-AP to
VEGF-165. Points and error bars represent mean ± SEM of duplicate or trip-
licate measurements. Curves are nonlinear fits to a single-site inhibition
equation, with fixed KD and concentration for the KDR-VEGF interaction as
described in Experimental Procedures.
(B) As in (A), but showing 6.64 Fab blocking.
Figure 4. KDR Mutant Binding ELISAs
Binding curves to 1121B Fab (A), 6.64 Fab (B), and VEGF-165 (C) are shown for KDR d1–3 mutants M2–M7 and d1–3 wild-type. Points and error bars represent
mean ± SEM of duplicate or triplicate measurements. Curves are nonlinear fits to a single-site binding equation. See Figure S3 and Table S1 for additional KDR
mutant binding data.
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Structure of Antibodies Bound to VEGF Receptor 2is poorly ordered. In any event, none of the residues in question
here make contacts to bound VEGF-C (Leppa¨nen et al., 2010).
One possible mechanism of 6.64 action is suggested by our
observation that 6.64 blocking of Fc-tagged KDR d1–3 or d1–7
is far weaker than its blocking of d1–7-AP, even though the anti-
body binding affinity to these three proteins is quite similar. Our
structure shows that 6.64 binds near the domain 3:domain 4
interface, and there is reason to think that domain 4 is involved
in KDR dimerization, both from analogy with c-Kit (Yuzawa
et al., 2007) and from electron microscopy of dimeric KDR:VEGF
complexes (Ruch et al., 2007). Even if bound 6.64 cannot steri-
cally interfere with receptor dimerization, the altered receptor
conformation could be an indirect interference producing the
same net result. The AP fusion of KDR domains 1–7, unlike the
two Fc fusions tested, does not have a covalent link between
the two monomers. This raises the possibility that antibody
binding could dissociate the receptor dimer completely, explain-
ing the enhanced blocking affinity of 6.64 against d1–7-AP (Fig-
ure 5B). Because 6.64 is known to be effective at blocking VEGF
signaling in cells (Witte et al., 1998), it seems that in this case the
d1–7-AP fusion is better than the Fc fusion atmimicking the natu-
rally occurring receptor dimer.
We designed our KDR mutants without knowledge of the
KDR:VEGF-C structure, in order to map the VEGF binding site;
however, they can also serve to test which residues contacting
VEGF-C are functionally important for binding VEGF-A. We
observed that mutant M5 (at the center of the 1121B binding
interface) eliminated 1121B binding without affecting 6.64
binding, whereas mutant M7 (in the 6.64 interface) had the
reverse effect, showing that the antibody epitopes are function-
ally as well as structurally separate. Neither of these mutants
affected VEGF binding; although Gly312 (changed to Ala in
mutant M5) is fairly close to Pro191 in VEGF-C, this contact is
too peripheral to be important for ligand binding. Mutant M2, in
contrast, targets residues in the middle of the VEGF-C interface,
in particular Leu252 and Asn253, and this mutant has a dramatic
effect on VEGF binding (Figure 4C). Mutant M8, in the linker
between KDR domains 2 and 3, had a modest effect on VEGF
binding, smaller than the 8-fold drop seen by Leppa¨nen et al.
when they replaced this sequence with the corresponding
sequence from VEGFR1. It seems likely that this region, which
is contacted by hydrophobic residues in VEGF-A and VEGF-C,
needs only to be hydrophobic. Mutation from valine to alanineStructure 19, 1097–is thus less disruptive than changing to the hydrophilic VEGFR1
sequence.
In conclusion, our structures of 1121B and 6.64 bound to KDR
domain 3 have shown two different ways to interfere with ligand-
receptor binding. 1121B acts in the classic way, by sterically pre-
venting VEGF from reaching its binding interface on the receptor.
Interestingly, 1121B can do this even though not a single resi-
due on KDR directly contacts both 1121B and VEGF-C. The
fact that the binding sites are immediately adjacent, and that
the 1121B and VEGF-C molecules extend beyond their foot-
prints on the KDR surface, is enough to induce the steric overlap
that prevents VEGF binding in the presence of 1121B. 6.64, by
contrast, appears to work more indirectly, perhaps by rearrang-
ing the domain 3:domain 4 interface of KDR in such a way that
the receptor can no longer dimerize. These modes of action
are not mutually exclusive: cetuximab binds to EGF receptor in
a way that blocks ligand binding and at the same time prevents
the receptor from adopting a conformation that would allow
dimerization and signaling (Li et al., 2005). These structures
show the multiple ways that an antibody drug can achieve its
clinical goal: disrupting a signaling pathway necessary for the
growth or survival of a cancer cell.
Significance
Inhibition of angiogenesis is an important strategy in treating
many diseases, frommacular degeneration to cancer. A number1107, August 10, 2011 ª2011 Elsevier Ltd All rights reserved 1103
Figure 6. Mechanism of Action of 1121B and 6.64
(A) Binding of 1121B, 6.64, and VEGF to KDR domain 3.
The KDR:1121B and KDR:6.64 structures have been
superimposed on their common KDR domain 3. KDR
domain 3 from the KDR:6.64 complex is shown in surface
representation, while the superimposed 1121B and 6.64
Fabs are shown in cartoon representation, colored as in
Figure 1. The contact patches (corresponding to the pink
and red coloring in Figure 2) are shown in brown for 1121B
and blue for 6.64. Additionally, the contact patch of VEGF-
C (Leppa¨nen et al., 2010) is shown in green.
(B) Steric clash between 1121B and VEGF. The KDR
d2–d3:VEGF-C structure (Leppa¨nen et al., 2010) is shown
in cartoon representation, with KDR colored magenta and
the two chains of VEGF-C colored black and white. The
superimposed KDR:1121B structure is shown with the
Fab in surface representation, colored as in Figure 1B.
The red patch in the foreground on the surface of 1121B
represents those atomswithin 2.2 A˚ of an atom in VEGF-C.
Additional red patches in the background indicate 1121B
atoms within 2.2 A˚ of an atom in the superimposed KDR
domain 2.
(C) Noninterference of 6.64 with the KDR:VEGF dimer. The
full dimer of KDR d2–d3 bound to VEGF-C (Leppa¨nen
et al., 2010) is shown in cartoon representation, colored
as in (B), while two copies of the 6.64 Fab, colored as
in Figure 1A, are superimposed on each copy of KDR
domain 3.
Structure
Structure of Antibodies Bound to VEGF Receptor 2of anticancer therapies have focused on disrupting the signaling
pathway involving vascular endothelial growth factors (VEGFs)
and their receptors, in particular VEGF receptor 2, or KDR. One
such therapy is a fully human anti-KDR antibody called IMC-
1121B, currently in phase III clinical trials. Our structure of the
Fab fragment of IMC-1121B in complex with domain 3 of KDR
reveals the molecular mechanism by which this antibody
prevents angiogenic signaling through KDR. This antibody
prevents all VEGF family ligands from binding to this receptor,
and has great promise as a broadly effective antiangiogenic
cancer therapy.1104 Structure 19, 1097–1107, August 10, 2011 ª2011 Elsevier Ltd All rights reservedEXPERIMENTAL PROCEDURES
See Supplemental Experimental Procedures for more
details on everything described below.
6.64 and 1121B Fab Production
1121B Fab was expressed and purified as previously
described (Miao et al., 2006). 6.64 Fab was cloned into
the mammalian expression pEE6.1 and pEE14.1 (Lonza
Biologics) and expressed in human 293 FreeStyle cells
(Invitrogen) by transient transfection. 6.64 Fab was puri-
fied from conditioned media by a multistep purification
including two passes over an SP-Sepharose HP column
(GE Healthcare) and one pass over a Superdex-200
column (GE Healthcare).
KDR Protein Production
KDR domain 3, containing residues Gly220–Ser328 of
human KDR with an N-terminal His tag, was expressed
in Hi5 insect cells (Novagen) and purified from conditioned
media by an Ni Sepharose HP column (GE Healthcare)
followed by a Superdex-200 column. The His tag was
then removed using factor Xa, and the KDR domain 3
was repurified by the Superdex-200 column. For themuta-genesis work, two KDR constructs, containing residues 20–328 (domains 1–3)
or residues 122–328 (domains 2–3) of human KDR, were cloned into a propri-
etary mammalian expression vector that produces the resulting protein
with a C-terminal Fc tag and an N-terminal CMV secretion signal sequence.
These wild-type proteins, and the mutants derived from them, were ex-
pressed in 293 FreeStyle cells by transient transfection, and then purified
from conditioned media by binding to a small protein A column, elution with
Gentle Elution Buffer (Pierce), and desalting using a PD-10 column (GE Life
Sciences).
Crystallization and Structure Determination
Purified KDR domain 3 was mixed with either the 6.64 Fab or the 1121B Fab,
with a slight molar excess of KDR, and allowed to incubate overnight at 4C.
Structure
Structure of Antibodies Bound to VEGF Receptor 2The complex was then purified away from excess KDR by a Superdex-200 gel
filtration column (GE Healthcare) and concentrated to 15–20 mg/ml for crystal-
lization trials. The concentrated crystallization stock was in 50 mM Tris (pH 8),
250 mM NaCl. Crystals were grown by hanging- and sitting-drop vapor diffu-
sion, with the protein stock mixed 1:1 with the well solution. For the KDR:6.64
complex crystals, the best well solution was 0.1MCdCl2, 0.1MNa acetate (pH
4.6), 30% (v/v) PEG 400. For the KDR:1121B complex crystals, the best well
solution was 0.1 M imidazole (pH 6.5), 0.1 M CaCl2, 40% (w/v) PEG 1500,
10% (v/v) isopropanol. The KDR:1121B crystallization condition produced
two different crystal forms, one with space group P3221 and one with space
group P43212 (see below); both forms would sometimes be present in the
same drop. Crystals of 1121B Fab alone were grown in 100mM sodium/potas-
sium phosphate (pH 5.5), 40% (v/v) PEG 400. All of these crystals could be
frozen in liquid nitrogen directly from the mother liquor due to the PEG 400
or isopropanol acting as a cryostabilizer. Data for the KDR:6.64 crystals and
for the KDR:1121B crystals (P3221 form) were collected at the LRL-CAT beam-
line (31-ID) at the Advanced Photon Source, Argonne National Laboratory.
Data for the KDR:1121B crystals (P43212 form) were collected at beamline
X4C at the National Synchrotron Light Source, Brookhaven National Labora-
tory. Data for the 1121B Fab crystals were collected on our home X-ray source,
a Rigaku MicroMax 007HF with Saturn-944 CCD detector. Data statistics can
be found in Table 1.
The 1121B Fab structure was solved by molecular replacement using
Phaser (McCoy et al., 2007), with the Fab fragment of cetuximab from the
cetuximab:EGFR structure (Protein Data Bank [PDB] ID code 1YY9) (Li et al.,
2005) as a search model. An initial solution for the KDR:6.64 structure was
also found by molecular replacement with search models of the Fab constant
and variable domains from PDB ID code 2VL5 (Uysal et al., 2008), chosen
because it is also a mouse IgG1 antibody. The KDR domain 3 in this complex
could not be found by molecular replacement; however, the electron density
was of sufficient quality to allow the molecule to be built by hand. The KDR
domain 3 model was refined using Refmac (Murshudov et al., 1997) over
several rounds, with TLS refinement and automatic water picking. The final
model contains all residues of KDR domain 3 from 220 to 328, plus one proline
at the N terminus from the factor Xa cleavage site.
The Fab portion of the KDR:1121B complex was found by molecular
replacement using the refined 1121B Fab structure as a search model,
whereas the KDR portion was found using the refined KDR domain 3 structure
from the KDR:6.64 complex. This solution, containing heavy and light chains of
the 1121B Fab as well as KDR domain 3, was refined with Refmac, using
limited TLS refinement and tight geometric restraints to prevent overfitting.
Some manual rebuilding of the Fab and KDR structures was necessary, espe-
cially in the area of the Fab:KDR interface, but we left most of the structure as
it was in the high-resolution models unless difference electron density clearly
defined an alternate position.
Binding and Blocking ELISAs
Binding ELISAs were performed by coating KDR d1-3-Fc wild-type, and the
mutants derived from it, on the surface of Immulon 2 HB plates (Thermo
Scientific), blocking, washing, and then applying serial dilutions of the appro-
priate binding partner (VEGF-165, 1121B Fab, or 6.64 Fab) and incubating at
room temperature for 1 hr. Secondary antibodies were matched to the binding
partner: for 6.64, 1121B, and VEGF, these were goat anti-mouse light chain
(Jackson ImmunoResearch), anti-human light chain (Jackson Immuno-
Research), and anti-VEGF polyclonal (R&D Systems), all of which were HRP
conjugated.
For the blocking ELISA, VEGF-165 was coated overnight on Immulon 2 HB
plates; the plates were then blocked and washed. Separately, serial dilutions
of 1121B Fab or 6.64 Fab were prepared in a solution containing phosphate-
buffered saline, 0.05% Tween-20, 1% milk powder, and 1 ng/ml KDR (this
corresponds to about 6.7 nM d1–7-AP, 9.1 nM d1–7-Fc, and 16 nM d1–3-Fc)
and then incubated for 1 hr at room temperature prior to addition to the plate.
The Fab:KDR mixtures were then added to the plates and incubated for
a further hour at room temperature, after which the plates were washed,
incubated with secondary antibody (HRP-conjugated anti-human Fc [Jackson
ImmunoResearch] for the Fc-tagged constructs, or His-Probe [Thermo Scien-
tific] for the AP construct, which also has a His tag), and developed. Ki values
were determined using the single-site Ki model in GraphPad Prism (GraphPadStructure 19, 1097–Software), with the concentrations of the ‘‘hot’’ ligands (the KDR constructs)
input as listed above, and the binding constants of the ‘‘hot’’ ligands to
VEGF (determined from other ELISAs) input as 2.4, 0.2, and 2.3 nM for
d1–7-AP, d1–7-Fc, and d1–3-Fc, respectively.ACCESSION NUMBERS
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